Pre-clinical studies have shown that MSCs’ EVs can inhibit the C5b-9 complex, reducing pro-inflammatory molecules such as IL-17, suggesting a potential therapeutic mechanism for psoriasis [218]. The gene discussed is IL17A; the disease is psoriasis.